[68] In ABCD1 knockout mice, overexpression of ABCD2 via thyroid receptor activation has been shown to decrease the accumulation of very long chain fatty acids (VLCFA).[68] Based on these findings, selective thyroid receptor agonists are being evaluated as a novel treatment for X-ALD, which is characterized by the accumulation of VLCFA.[68] However, inhibition of fatty acid accumulation and oxidation has been shown to reduce GBM proliferation,[69] growth,[70] and survival[71] as well. Here, ABCD2 is linked to X-linked adrenoleukodystrophy.